A post hoc analysis of the effect of weight on efficacy in depressed patients treated with desvenlafaxine 50 mg/d and 100 mg/d

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 17, Issue 3, 2015, Pages

  McIntyre, Roger S ^a   Fayyad, Rana S ^b   Guico Pabia, Christine J ^b,c   Boucher, Matthieu ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PFIZER INC   (United States)

^c CGP Strategic Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBESITY; POST HOC ANALYSIS; REMISSION; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84944339602     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.14m01741     Document Type: Article

References (39)

1. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51(5):274-280. PubMed.
2. McIntyre RS, Alsuwaidan M, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24(1):69-81. PubMed.
3. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229. PubMeddoi:10.1001/archgenpsychiatry.2010.2.
4. de Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230-235. PubMed doi:10.1016/j.psychres.2009.04.015.
5. Pan A, Sun Q, Czernichow S, et al. Bidirectional association between depression and obesity in middle-aged and older women. Int J Obes (Lond). 2012;36(4):595-602. PubMeddoi:10.1038/ijo.2011.111.
6. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272. PubMed doi:10.4088/JCP.09r05346blu.
7. Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124(4):154-167. PubMed doi:10.3810/pgm.2012.07.2577.
8. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry. 2004;16(1):15-25. PubMed doi:10.1080/10401230490281618.
9. Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011;14(3):367-375. PubMeddoi:10.1017/S1461145710000933.
10. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006;8(5):269-278. PubMeddoi:10.4088/PCC.v08n0503.
11. Khan A, Schwartz KA, Kolts RL, et al. BMI, sex, and antidepressant response. J Affect Disord. 2007;99(1-3):101-106. PubMed doi:10.1016/j.jad.2006.08.027.
12. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321-326. PubMed doi:10.1016/j.biopsych.2006.10.001.
13. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):59-63. PubMed doi:10.1017/S1461145704004602.
14. Uher R, Mors O, Hauser J, et al. Body weight as a predictor of antidepressant efficacy in the GENDEP project. J Affect Disord. 2009;118(1-3):147-154. PubMed doi:10.1016/j.jad.2009.02.013.
15. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc; 2013.
16. Pristiq [product monograph]. Kirkland, Quebec: Pfizer Canada Inc; 2013.
17. Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(1):e1-e8. PubMed.
18. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677-688. PubMed doi:10.4088/JCP.v68n0504.
19. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877-1890. PubMed doi:10.1185/03007990802161923.
20. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243-253. PubMed doi:10.1097/YIC.0b013e32830cebed.
21. Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31(pt 1):1405-1423. PubMed doi:10.1016/j.clinthera.2009.07.006.
22. Iwata N, Tourian KA, Hwang E, et al, for the Study 3359 Investigators. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients.J Psychiatr Pract. 2013;19(1):5-14. PubMed doi:10.1097/01.pra.0000426323.59698.64.
23. Liebowitz MR, Tourian KA, Hwang E, et al; Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013;13(1):94. PubMed doi:10.1186/1471-244X-13-94.
24. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74(10):1010-1017. PubMed doi:10.4088/JCP.12m08065.
25. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31(5):569-576. PubMed doi:10.1097/JCP.0b013e31822c0a68.
26. Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry. 2013;74(2):158-166. PubMed doi:10.4088/JCP.12m07974.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. PubMed doi:10.1136/jnnp.23.1.56.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
31. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976. PubMeddoi:10.1192/bjp.134.4.382 GuyGuy W. ECDEGGGGGGjjjjjjkU Assessment Mdanual for Psychopharmacology-Revised. RGuy W. ECDEGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, andddddddd Welfare; 1976.U Assessment Manual for Psychopharmacology-Revised. RoGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rossssssckville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.ckville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.ockdvGgille, MD: National Institute of Health, DepartmGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.ent of Health, Education, and Welfare; 1976.Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.Guy W. ECDEU Assessment MGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.anual for PsychopharmacologGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.-Revised. RockvGuy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.ille, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Health, Department of Health, Education, and Welfare; 1976.ddddd.
32. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:113-115.
33. World Health Organization. Wellbeing measures in primary health care/the depcare project. World Health Organization Regional Office for Europe.http://www.euro.who.int/__data/assets/pdf_file/0016/130750/E60246.pdf. Accessed March 20, 2012.
34. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63(9):826-837.PubMed doi:10.4088/JCP.v63n0913.
35. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-855. PubMed doi:10.1001/archpsyc.1991.01810330075011.
36. Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research group. Defining remission by cutoff score on the MADRS: selecting the optimal value. J Affect Disord. 2002;72(2):177-184.PubMed doi:10.1016/S0165-0327(01)00451-7.
37. Oskooilar N, Wilcox CS, Tong ML, et al. Body mass index and response to antidepressants in depressed research subjects. J Clin Psychiatry. 2009;70(11):1609-1610. PubMeddoi:10.4088/JCP.09l05226blu.
38. Lin CH, Chen CC, Wong J, et al. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. J Affect Disord. 2014;161:123-126. PubMeddoi:10.1016/j.jad.2014.02.039.
39. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients: findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009;43(3):215-229. PubMed doi:10.1016/j.jpsychires.2008.05.002.